Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transciptome profiling of 18 breast cancer cell llines

ABSTRACT: Transciptome profiling of 18 breast cancer cell llines

PROVIDER: PRJNA638351 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11965600_1.fastq.gz	Fastqsanger.gz
	SRR11965600_2.fastq.gz	Fastqsanger.gz
	SRR11965601_1.fastq.gz	Fastqsanger.gz
	SRR11965601_2.fastq.gz	Fastqsanger.gz
	SRR11965602_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 204

Similar Datasets

Transciptome profiling of 18 breast cancer cell llines

Project description:Transciptome profiling of 18 breast cancer cell llines as part of a drug screen to identify mechanisms of response and resistance for each compound and find biomarkers doi: 10.7554/eLife.57894

2020-06-16 | GSE152102 | GEO

Transciptome profiling of ovarian cancer cell lines

Project description:Transciptome profiling of ovarian cancer cell lines

| PRJEB2562 | ENA

Proteome characterization of Breast Cancer Cell lines

Project description:Protein profiling of 18 breast cancer cell lines in triplicates using TMT10-plex.

2020-07-04 | PXD013276 | JPOST Repository

The polycomb protein MEL-18/PCGF2 regulates ErbB phosphorylation in HER2-positive breast cancer

Project description:Gene expression analysis on MEL-18-knockdown BT474 cells. MEL-18, a polycomb group protein and a member of the polycomb repressive complex 1 (PRC1), have suggested as a tumor suppressor in several cancer, including breast cancer. The results provides that the depletion of MEL-18 in HER2-positive breast cancer causes the activation of ErbB signaling pathway. We proposed that MEL-18 is a novel prognostic and therapeutic marker for HER2-positive breast cancer.

2018-07-31 | GSE92504 | GEO

Effect of MEL-18 knockdown on estrogen-sensitive MCF7 breast cancer cells

2015-05-01 | GSE64716 | GEO

Effect of MEL-18 knockdown on estrogen-sensitive MCF7 breast cancer cells

Project description:Gene expression analysis of MEL-18-silenced MCF7 cell lines. MEL-18 is a component of the polycomb repressive complex (PRC)-1, which is a critical epigenetic modulator of stem cell regulation and normal and cancerous development. Accumulating studies have suggested that MEL-18 might act as a tumor suppressor in several human tumors, including breast cancer. Results provide insight into the functional role of MEL-18 in estrogen-dependent breast cancer. MCF7 cells stably infected with lentiviruses encoding either control (shCon) or MEL-18 shRNA (shMEL) were cultured in phenol-red free DMEM supplemented with 10% FBS for 48 h. Total RNA was isolated from the cultures using Trizol reagent. For each of the 2 conditions, 2 biological replicates were included. In total, 4 microarray samples were analyzed; 2 controls and 2 shRNA MEL-18 knockdowns. All labeling, hybridization and scanning steps were performed according to the manufacturers’ instructions.

2015-05-01 | E-GEOD-64716 | biostudies-arrayexpress

Breast cancer development model

Project description:Breast cancer development model

2020-10-08 | 627 | FAIRDOMHub

Transcriptome profiling of MDA-MB-231 cells following the MEL-18 phosphorylation at T334

Project description:RNA-sequencing analysis of MEL-18 WT- or MEL-18 T334A-overexpressing MDA-MB-231 cell lines. MEL-18, a core component of polycomb-repressive complex (PRC)-1, has been known to be phosphorylated at multiple residues in vitro; however, its functional roles in mammalian cells and human cancer remains largely unknown. Here, we examined the effect of MEL-18 phosphorylation at T334 site on polycomb-mediated epigenetic silencing in human breast cancer. Our results demonstrated that the phosphorylation of MEL-18 at T334 alters its genomic distribution and transcriptional activity that reflects functional change of MEL-18 in modulating breast tumour progression.

2022-03-01 | GSE115591 | GEO

In-depth membrane proteomic study of breast cancer tissues

Project description:Human breast cancer tissue samples from 18 patients with high-risk or low-risk MammaPrint breast cancer were analyzed. The membrane fractions were enriched, and the extracted proteins were reduced, alkylated, digested with Lys-C and Trypsin, and labelled with iTRAQ4plex: 114; high risk; 115; low risk. Identification results were filtered at 1% false discovery rate (FDR) thresholds by searching against a randomized decoy database using Mascot at peptide and protein levels.

2016-10-17 | PXD005163 | JPOST Repository

Breast-cancer

Project description:Breast-cancer paper

| PRJEB21010 | ENA